期刊文献+

循环应用低剂量环磷酰胺联合过继免疫治疗的抗黑色素瘤作用 被引量:3

The anti-melanoma effect of cyclical administration of low-dose cyclophosphamide combined with cellular immunotherapy
下载PDF
导出
摘要 目的:观察循环应用低剂量环磷酰胺(CTX)对荷瘤鼠调节性T细胞(Tregs)的影响,及联合细胞毒性T细胞(CTLs)过继免疫治疗的实际抗瘤效果并探讨其中可能的机制。方法:通过皮下接种瘤细胞制备黑色素瘤荷瘤鼠模型;腹腔注射CTX,每隔7天给药一次,共3次;应用流式细胞术检测小鼠脾脏中CD4+CD25+Foxp3+调节性T细胞(Tregs)的变化。体外培养小鼠骨髓来源的树突状细胞(DCs),制备肿瘤抗原特异性的CTLs。在腹腔注射CTX后4天,鼠尾静脉注射CTLs,每隔7天治疗一次,共3次。绘制各组肿瘤生长曲线。结果:随着荷瘤时间的延长,荷瘤鼠CD4+CD25+Foxp3+/CD4+比例逐渐升高。循环应用CTX能够延长对Tregs的抑制,维持其在相对较低水平。循环CTX+CTLs疫苗治疗组的抑瘤作用最为明显(P<0.05);治疗组中未见免疫性白斑等自身免疫病及明显化疗毒副反应。结论:循环应用低剂量CTX能够规律有效地调控Tregs,显著提高CTLs过继免疫治疗的疗效。 Objective :To observe the influence of cyclical low-dose cyclophosphamide (CTX) administration on regulatory T cell of melanoma-bearing mice, and the anti-tumor effects of combination with CTLs adoptive transfusion, explore its possible mechanism. Methods: Models of tumor-bearing mice were established by subcutaneous inoculation with melanoma cells. The changes of the CD4 ^+ CD25 ^+ Foxp3^ + Treg in spleens were detected by flow cytometry. The dendritic cells derived from the bone marrow of mice were cultured, and the tumor antigen-specific CTLs were prepared by cultivation in vitro. Tumor-bearing mice were injected intraperitoneally with CTX every 7 days, then received CTLs by veinous transfusion 4 days later, which were repeated 3 cycles. The growth curves of tumor were drawn. Results : With time prolonged after tumor inoculation, the proportion of CD4 ^+ CD25 ^+ Foxp3 ^+/CD4 ^+ was increased gradually in mice. Single administration of CTX only inhibited Tregs in short time, while cyclical administration of CTX could prolong the period in which Tregs was kept at low level. Cyclical administration of CTX could not delay the growth of tumor. But the tumor growth was delayed more significantly in cyclical CTX + CTLs group ( P 〈 0.05 ), autoimmune vitiligo and other adverse side effect were not observed in mice treated with CTX. Conclusion: Cyclical administration of low-dose CTX could enhence the anti-tumor effect of CTLs adoptive transfusion by regulating Tregs.
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2013年第4期395-399,共5页 Chinese Journal of Immunology
基金 河北省科技支撑计划项目资助(09276418D-26,10246139D)
关键词 调节性T细胞 环磷酰胺 黑色素瘤 细胞毒性T细胞 过继性细胞免疫治疗 Regulatory T cell Cyclophosphamide Melanoma Cytotoxic T lymphocytes Adoptive cellular immunotherapy
  • 相关文献

参考文献8

  • 1Rosenberg S A. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know[J]. Nat Rev Clin Oncol, 2011; 8 (10) :577-585.
  • 2Cao X. Regulatory T cells and immune tolerance to tumors [ J ]. Immunol Res, 2010 ; 46( 1-3 ) :79-93.
  • 3Brode S, Cooke A. Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide [J]. Crit Rev Immunol, 2008; 28 (2) :109-126.
  • 4Schabowsky R H, Madireddi S, Sharma R et al. Targeting CD4^+ CD25^+ FoxP3^+ regulatory T-cells for the augmentation of cancer immunotherapy [J]. Curr Opin Investig Drugs, 2007 ; 8 ( 12 ) : 1002-1008.
  • 5Golovina T N, Vonderheide R H. Regulatory T cells: overcoming suppression of T-cell immunity [ J ]. Cancer J, 2010; 16 (4): 342 -347.
  • 6Strauss L, Bergmann C, Szczepanski Met al. A unique subset of CD4^+ CD25^high Foxp3^+ T cells secreting interleukin-10 and transforming growth factor-betal mediates suppression in the tumor microenvironment[ J]. Clin Cancer Res, 2007 ; 13 (15) : 4345-4354.
  • 7Matsushita N, Pilon-Thomas S A, Martin L M et al. Comparative methodologies of regulatory T cell depletion in a murine melanoma model [ J ]. J Immunol Methods, 2008, 333 ( 1-2 ) : 167-179.
  • 8Schippling D S, Martin R. Spotlight on anti-CD25: daclizumab in MS[J]. Int MS J, 2008;15(3) :94-98.

同被引文献69

  • 1赵辨.中国临床皮肤病学[M].南京:江苏科学技术出版社,2009,12:744.
  • 2Quah BJ,Parish CR. The use of carboxyfluorescein diacetate succin- imidyl ester (CFSE) to monitor lymphocyte proliferation [ J ]. J Vis Exp,2010,12(44) :2259-2261.
  • 3Sharahi A, Haran-Ghera N. Immune reeovey after cyclophosphmnide treatment in muhiple myeloma:implieation for maintenance immuno- therapy [ J ]. Bone Marrow Res,2011,2011:269519.
  • 4Shi H, Liu L, Wang Z. Improving the efficacy and safety of engineered T cell therapy for cancer[ J ] Cancer Lett ,2013,328 ( 2 ) : 191-197.
  • 5Jarnieki AG, Lysaght .1 ,Todryk S, et al. Suppression of antitumor im- nmnity by IL-10 and TGF-beta-producing T cells infiltrating the grow- ing tumor:influence of tumor environment on the induction of CD4 + and CD8 + regulatory T eells[ J ]. J Immunol, 2006,177 (2) : 896- 904.
  • 6Kim S, Buehlis G, Fridlender ZG, et al. Systemic blockade of transfor- nfing growth factor-beta signaling augments the efficiency of immuno- enetheraov [ J]. Cancer Res. 2008.68 ( 24 ) 10247 -10256.
  • 7Hassin D, Garber OG, Meiraz A, et al. Cytotoxic T lymphocyte perforin and Fas ligand working in concert even when Fas ligand lytic action is still not detectable [ J ]. hnnmnology, 2011,133 ( 2 ) : 190 - 196.
  • 8Rega A, Terlizzi M, Luciano A, et al. Plasmacytoid dendritic cells play a key role in tumor progression in lipopolysaccharide stimulated lung tumor bearing mice[J]. Immunol, 2013, 190(5): 2391-2402.
  • 9Sharabi A, Ghera NH. Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapy[J]. Adv Cancer Res, 2010, 107: 1-37.
  • 10Wada S, Yoshimura K, Hipkiss EL, et al. Cyclophosphamide augments antitumor Immunity: studies in an autochthonons prostate cancer model[J]. Cancer Res, 2009, 69(10): 4309-4318.

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部